Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ResMed

Is ResMed Stock Outperforming the Dow?

Despite ResMed’s outperformance relative to the Dow Jones over the past year, analysts are cautiously optimistic about the stock’s prospects.

ResMed Shows Market Leadership With Jump To 81 RS Rating

ResMed Shows Market Leadership With Jump To 81 RS Rating

ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 74 to 81.

Investors Business Daily

ResMed Among Top Stocks For Recent And Long-Term Profit Growth

ResMed Among Top Stocks For Recent And Long-Term Profit Growth

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

The global sleep crisis is costing companies. These 3 things are driving it.

Globally, 71% of employed respondents have called in sick due to poor sleep at least once in their career.

Stocks With Rising Relative Strength: ResMed

A Relative Strength Rating upgrade for ResMed shows improving technical performance. Will it continue?

Investors Business Daily

ResMed Close To Joining Very Elite Stock Group

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

Dow Jones Futures Rise; S&P 500 Nears High As Apple Triggers Buy Signal

The Dow and S&P 500 are near all-time highs early Friday as Apple stock flashes a buy signal. Deckers and Atlassian diverged on earnings.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?

ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

Investors Business Daily

ResMed Receives IBD Stock Rating Upgrade

ResMed Receives IBD Stock Rating Upgrade

On Wednesday, ResMed got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96.

Investors Business Daily

ResMed's Quarterly Earnings Preview: What You Need to Know

ResMed's Quarterly Earnings Preview: What You Need to Know

ResMed is expected to release its fiscal second-quarter earnings this month, and analysts project a double-digit profit growth.

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly's Obesity Drug Wins Approval In Sleep Apnea; Will ResMed Dive?

Eli Lilly gained FDA approval late Friday for its weight-loss drug, Zepbound, as a treatment for obstructive sleep apnea.

Investors Business Daily

Is ResMed Stock Outperforming the Nasdaq?

Is ResMed Stock Outperforming the Nasdaq?

ResMed has outpaced the broader Nasdaq Composite index over the past year, and Wall Street analysts are moderately bullish about the stock’s prospects.

ResMed Stock: Is Wall Street Bullish or Bearish?

ResMed Stock: Is Wall Street Bullish or Bearish?

Although ResMed has outperformed relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook about the stock’s prospects.

Fabric face mask to help apnoea sufferers rest easy

Fabric face mask to help apnoea sufferers rest easy

After double-digital sales growth last quarter, ASX-listed medical device maker ResMed has launched a product its CEO had been dreaming about for a decade.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

ResMed Is 80 And 80: Hits 80-Plus Relative Strength Rating After Rising 80% In A Year

ResMed shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Investors Business Daily

Stocks Showing Market Leadership: ResMed Earns 92 RS Rating

ResMed shows rising price performance, earning an upgrade to its IBD Relative Strength Rating.

Investors Business Daily

S&P 500 Giant Leads 5 Stocks Near Buy Points

S&P 500 giant JPMorgan Chase has been hovering near a buy point since a Q3 earnings beat. Several stocks are in or near buy zones.

Investors Business Daily

ResMed Breaks Out As GLP-1 Drugs And Big Tech Help Drive A Quarterly Beat

ResMed stock broke out early Friday after the CPAP maker broadly beat third-quarter projections, shrugging off weight-loss drug worries.

Get all your
news in one place.

100’s of premium titles.
One news app.

ResMed's Q1 2025 Earnings: What to Expect

ResMed is scheduled to report its first-quarter earnings later this month, and analysts project a double-digit rise in its bottom line.

Is ResMed Stock Outperforming the S&P 500?

ResMed has recently outperformed the S&P 500, and Wall Street analysts are moderately bullish about the stock’s prospects.

ResMed Stock: Analyst Estimates & Ratings

Despite ResMed’s outperformance relative to the broader market over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

Weight-loss drugs not lights out for ResMed: CEO

Sleep apnoea device manufacturer ResMed has continued to see revenue and net income grow, despite short-sellers claiming weight loss drugs threaten its market.

Five Stocks With Solid Growth History and a Promising Outlook

Five reasonably priced stocks with solid growth history and a good chance of delivering earnings even if the economy softens.

Investors Business Daily

Eli Lilly's Weight-Loss Drug Takes Down ResMed, Inspire Medical — Again

ResMed stock and Inspire Medical Systems stock tumbled Monday after Eli Lilly said its weight-loss drug reduced sleep apnea events.

After Blowout Earnings, This Dividend Stock Still Looks Cheap

Despite its remarkable post-earnings rally, here's a dividend stock that still carries a bargain tag.

People

100,709 stories

Samik Chatterjee

Margaret Kaczor Andrew

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intel Corporation

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

253,621 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play